Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
276.0
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
30.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible
110.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
55.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
36.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
140.0
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
72.0
Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder; HIV-positive patients on combination antiretroviral therapy are ineligible
80.0
HIV-positive patients on combination antiretroviral therapy are ineligible
30.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
73.0
HIV-positive patients on combination antiretroviral therapy are ineligible
80.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
70.0
Human immunodeficiency virus (HIV) positive patients on antiretroviral therapy are ineligible
72.0
TREATMENT: HIV-positive patients on combination antiretroviral therapy are ineligible
700.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
40.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; it is not necessary to conduct HIV testing at screening; patients who are HIV-positive with undetectable viral loads, not on interacting antiretroviral therapy, and have CD4 counts above 300/mm^3 may be eligible after discussion with the principal investigator
68.0
HIV-positive patients on combination antiretroviral therapy are ineligible
68.0
Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible
32.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
100.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
24.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
35.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
40.0
HIV-positive patients on combination antiretroviral therapy are ineligible
35.0
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
340.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
90.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
23.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
18.0
Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
60.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
66.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
58.0
Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
126.0
Patient does not have known human immunodeficiency virus syndrome (HIV, testing optional); known HIV-positive patients receiving combination antiretroviral therapy are ineligible
188.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
82.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
126.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy known to interact with CYP isoenzymes are ineligible; in addition, HIV patients with CD4 count < 200 cells/uL are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
37.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
36.0
Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible
50.0
Patients who are known to be human immunodeficiency positive (HIV)-positive and are on combination antiretroviral therapy are ineligible
15.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
46.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
180.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
46.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
70.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
48.0
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
60.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; patients must also have a CD4 count > 350 cells/mm^3 with an undetectable viral load
35.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
28.0
Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
180.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are INELIGIBLE
40.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
132.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
40.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
70.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
30.0
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible due to potential drug-drug interactions with PT2385
35.0